GGrantIndex
Sort

17,288 grants matching multiple sclerosis

From therapeutic mechanisms to unraveling the pathophysiology of MS

$1,497,510
Bibiana Bielekova · National Institute Of Neurological Disorders And Stroke · ZIA · FY2013 · NS

Mechanisms of molecular machines that regulate the neuronal cytoskeleton

$1,497,271
Antonina Roll-Mecak · National Institute Of Neurological Disorders And Stroke · ZIA · FY2015 · NS

CTE and Posttraumatic Neurodegeneration: Neuropathology and Ex Vivo Imaging

$1,496,457
Ann Carolyn McKee · Boston University Medical Campus · U01 · FY2016 · NS

Genetic and Environmental Risk Factors for Hemorrhagic Stroke

$1,496,347
Daniel Woo · University Of Cincinnati · U01 · FY2016 · NS

NINDS Quantitative MRI Core Facility

$1,496,165
Govind Bhagavatheeshwaran · National Institute Of Neurological Disorders And Stroke · ZIC · FY2022 · NS

Dissecting Functional Autoimmunity through High-Resolution Multiomics in a Vitiligo Center of Research Translation (V-CoRT)

$1,495,911
John E Harris · Univ Of Massachusetts Med Sch Worcester · P50 · FY2025 · AR

Center for Research Translation in Scleroderma

$1,494,942
Frank C Arnett · University Of Texas Hlth Sci Ctr Houston · P50 · FY2006 · AR

Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD

$1,492,509
Samuel V Alworth · Acurastem, Inc. · R44 · FY2023 · AG

Detection of Prions

$1,491,280
Byron Caughey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

$1,489,811
Sunil Gandhi · Savanna Biotherapeutics, Inc. · R44 · FY2025 · NS

Development of Pathology-activated Drugs for Treatment of Neuropathic Pain

$1,485,925
Peter M Grace · University Of Tx Md Anderson Can Ctr · UH3 · FY2024 · NS

Developing a PET tracer targeting myeloperoxidase activity for neurodegenerative diseases

$1,484,822
John W Chen · Massachusetts General Hospital · RF1 · FY2022 · AG

Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways

$1,481,400
Matthew D Disney · Scripps Florida · P01 · FY2017 · NS

Developmental Control Of Gene Expression In The Brain

$1,477,823
Lynn D Hudson · Neurological Disorders And Stroke · Z01 · FY2007 · NS

Genetic and Environmental Risk Factors for Hemorrhagic Stroke

$1,476,033
Daniel Woo · University Of Cincinnati · U01 · FY2020 · NS

Targeting Remyelination to Treat Preterm Brain Injury

$1,476,000
Bridget Lamonica Ostrem · University Of California, San Francisco · DP2 · FY2025 · NS

THERAPEUTIC REMYELINATION STRATEGIES IN A NOVEL MODEL OF MULTIPLE SCLEROSIS: JAPANESE MACAQUE ENCEPHALOMYELITIS

$1,476,000
Oregon Health & Science University · · FY2009 · Department of the Army

Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding

$1,473,895
Edward Burgard · Dignify Therapeutics, Llc · U44 · FY2024 · NS

Genetic and Environmental Risk Factors for Hemorrhagic Stroke

$1,469,200
Daniel Woo · University Of Cincinnati · U01 · FY2019 · NS

Nuclear receptors: action, functions, and roles in disease

$1,461,795
Anton M Jetten · National Institute Of Environmental Health Sciences · ZIA · FY2011 · ES

DEMYELINATING DISEASE: VIRAL AND IMMUNE FUNCTION

$1,461,289
University Of Southern California · P01 · FY2003 · NS

Functions and Mechanisms of NF-kB Factors and their Regulators

$1,459,824
Philip Murphy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Evaluation of clinical samples for virus detection for CNS disease

$1,458,521
Eugene O. Major · National Institute Of Neurological Disorders And Stroke · Z01 · FY2008 · NS

Implementing a coupled system of integrative ML modeling and data validation for elucidating microglial therapeutic targets in neurodegenerative disease

$1,457,344
Karen Sachs · Modulo Bio, Inc. · R44 · FY2023 · MH

Pragmatic Trials in Maintenance Hemodialysis

$1,455,463
Laura M Dember · University Of Pennsylvania · UH3 · FY2013 · DK